AT7519

• UNSPSC Description:

  AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

• Target Antigen:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/at7519.html

• Purity:

  99.76

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl

• Molecular Weight:

  382.24448

• References & Citations:

  [1]Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36.|[2]Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.|[3]Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.Adv Sci (Weinh). 2024 Jan 6:e2305260.|bioRxiv. 2024 September 07.|Dev Biol. 2024 Jan 28:508:93-106.|Exp Eye Res. 2023 Jan 22;227:109391.|FASEB J. 2024 Apr 30;38(8):e23628.|Glycobiology. 2022 Jun 16;cwac038.|Harvard Medical School LINCS LIBRARY|Oncogene. 2023 Oct 16.|RNA Biol. 2021 Sep 30;1-8.|Sci Rep. 2021 Mar 8;11(1):5374.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.|Harvard Medical School LINCS LIBRARY

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  844442-38-2